GLP-1
glucagon-like peptide-1 (agonists) — The drug class behind Ozempic and Wegovy — obesity and diabetes treatments reshaping pharma pipelines and food-industry forecasts.
Coverage of GLP-1 is holding steady : 7 signals on the latest tracked day, up 133% from its three-week baseline of 3, across 6 domains (up from 3 a week ago). That makes it the #314 most-covered of the 348 concerns we track.
What’s changed
5 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.
- GLP-1 Drug Semaglutide Slows Aging and Extends Lifespan in Mice · GEN - Genetic Engineering & Biotechnology News · 2026-09-03
- Beyond food noise: could GLP-1 medications change the way we experience cravings? · Nutraceutical Business Review · 2026-09-03
- GLP-1 Coverage Fell From 72% to 60%. Is Eli Lilly’s Weight-Loss Boom Hitting an Insurance Wall? · 24/7 Wall St. · 2026-08-29
- Trump GLP-1 update teases blockbuster annual sales for Lilly from Medicare program: analyst · Fierce Pharma · 2026-09-03 · usually covers FDA Decisions
- GLP-1 agonist semaglutide slows aging in mice · Chemical & Engineering News · 2026-09-03 · usually covers Chemicals
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · FDA — What's New: Drugs · 2026-09-02 · usually covers Biotech Pharma
What the reporting says
Across 55 tracked stories from 29 outlets, reporting on GLP-1 most often describes regulatory approvals (9), launches or releases (2), elections (1), public statements (1), meetings or visits (1).
It shows up alongside Eli Lilly (11), FDA (17).
Two steps out: AI (through FDA, 17 shared stories on the weaker link); Biological Products (through FDA, 17 shared stories on the weaker link); Cder (through FDA, 17 shared stories on the weaker link); Colorectal Cancer (through FDA, 17 shared stories on the weaker link).
Tracked since Apr 6, with coverage on 23 separate days — concentrated in Auto.